Literature DB >> 27310099

Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND study).

Young Sup Woo1, Roger S McIntyre2, Jung-Bum Kim3, Min-Soo Lee4, Jae-Min Kim5, Hyeon Woo Yim6, Tae-Youn Jun7.   

Abstract

BACKGROUND: Available studies indicate that obesity may exert a moderational effect on antidepressant treatment response. The aim of this study was to investigate the relationship between treatment response and metabolic abnormalities amongst patients with depressive disorders in a large naturalistic clinical setting.
METHODS: A nationwide prospective study was conducted in 18 hospitals in South Korea; 541 depressive patients meeting DSM-IV criteria were recruited. After baseline evaluation, subjects received naturalistic clinician-determined antidepressant interventions. Assessment was performed at baseline and weeks 1, 2, 4, 8, 12, 24 and 52. Treatment response was defined as a ≥50% reduction from baseline on at least one evaluation point.
RESULTS: In univariate comparison, the patients who showed insufficient response to antidepressant therapy were more likely to be male, unmarried, unemployed, and obese. After adjusting for baseline variables, male sex (OR=1.82) and obesity (OR=1.55) remained as were significant variables. Stratification of the subjects into one of three groups, i.e. male, pre-menopausal female and post-menopausal female, revealed that males with concurrent metabolic problems, (i.e. the presence of one or more of hypertension, hyperglycemia, or hypercholesterolemia) had significantly higher risk for insufficient response (OR=2.32) and, after adjusting for baseline variables, obesity predicted insufficient response in post-menopausal female (OR=2.41).
CONCLUSIONS: The presence of metabolic abnormalities in patients with depressive disorders was associated with decreased treatment response to antidepressants. These results underscore the neurobiological relationship between obesity and the central nervous system, and provide empiric evidence supporting stratification of treatment response in depression.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressant; Depression; Gender difference; Menopause; Metabolic abnormalities; Treatment outcome

Mesh:

Substances:

Year:  2016        PMID: 27310099     DOI: 10.1016/j.jad.2016.06.018

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

1.  Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance.

Authors:  John S Mulvahill; Ginger E Nicol; David Dixon; Eric J Lenze; Jordan F Karp; Charles F Reynolds; Daniel M Blumberger; Benoit H Mulsant
Journal:  J Am Geriatr Soc       Date:  2017-12       Impact factor: 5.562

2.  Brain structural networks and connectomes: the brain-obesity interface and its impact on mental health.

Authors:  Vincent Chin-Hung Chen; Yi-Chun Liu; Seh-Huang Chao; Roger S McIntyre; Danielle S Cha; Yena Lee; Jun-Cheng Weng
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-26       Impact factor: 2.570

Review 3.  Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness.

Authors:  Victor Mazereel; Johan Detraux; Davy Vancampfort; Ruud van Winkel; Marc De Hert
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-09       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.